Brought to you by 
Alnylam Pharmaceuticals licenses Max Planck patents
05 Nov 2020
Executive Summary
Recently founded drug development company Alnylam Pharmaceuticals has licensed various patents in the area of RNA interference (RNAi) from the Max Planck Society, through the latter's tech transfer office Garching Innovation GMBH.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alnylam Pharmaceuticals licenses Max Planck patents
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice